TY - JOUR
T1 - Analysis of Candida auris fungemia at a single facility in Kenya
AU - Adam, Rodney D.
AU - Revathi, Gunturu
AU - Okinda, Nancy
AU - Fontaine, Melanie
AU - Shah, Jasmit
AU - Kagotho, Elizabeth
AU - Castanheira, Mariana
AU - Pfaller, Michael A.
AU - Maina, Daniel
N1 - Publisher Copyright:
© 2019 The Authors
PY - 2019/8
Y1 - 2019/8
N2 - Objectives: Candida auris emerged as a human pathogen in 2009 and has subsequently been identified around the world as a cause of invasive candidiasis. We did an analysis from a single institution in order to analyze risk factors and outcomes for C. auris candidemia. Methods: Patients with candidemia were identified by the electronic medical record and reviewed for risk factors and outcome. Candida isolates were identified by Vitek2 as Candida haemulonii, but species determinations for 21 of the isolates using published molecular and proteomic methods identified all as C. auris. Findings: From September 2010 to December 2016, C. auris accounted for 38% of 201 patients with candidemia, while C. albicans contributed 25%. C. auris patients had been hospitalized longer (mean 32 days vs. 13 days; p < 0.001), were more likely to have central lines preceding candidemia than C. albicans patients (84% vs. 54%; p = < 0.001) and had more commonly been treated with carbapenems (83% vs 61% for C. albicans [p = 0.01]). The crude mortality was 29%, compared to 36% for C. albicans. Conclusions: These findings suggest an opportunistic pathogen that may be less virulent, but difficult to eradicate and that control efforts should focus on antimicrobial usage.
AB - Objectives: Candida auris emerged as a human pathogen in 2009 and has subsequently been identified around the world as a cause of invasive candidiasis. We did an analysis from a single institution in order to analyze risk factors and outcomes for C. auris candidemia. Methods: Patients with candidemia were identified by the electronic medical record and reviewed for risk factors and outcome. Candida isolates were identified by Vitek2 as Candida haemulonii, but species determinations for 21 of the isolates using published molecular and proteomic methods identified all as C. auris. Findings: From September 2010 to December 2016, C. auris accounted for 38% of 201 patients with candidemia, while C. albicans contributed 25%. C. auris patients had been hospitalized longer (mean 32 days vs. 13 days; p < 0.001), were more likely to have central lines preceding candidemia than C. albicans patients (84% vs. 54%; p = < 0.001) and had more commonly been treated with carbapenems (83% vs 61% for C. albicans [p = 0.01]). The crude mortality was 29%, compared to 36% for C. albicans. Conclusions: These findings suggest an opportunistic pathogen that may be less virulent, but difficult to eradicate and that control efforts should focus on antimicrobial usage.
KW - Antimicrobial stewardship
KW - Candida auris
KW - Candidemia
KW - Carbapenems
KW - Central venous catheters
UR - http://www.scopus.com/inward/record.url?scp=85068379452&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2019.06.001
DO - 10.1016/j.ijid.2019.06.001
M3 - Article
C2 - 31185293
AN - SCOPUS:85068379452
SN - 1201-9712
VL - 85
SP - 182
EP - 187
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
ER -